Structure via PubChem · Public domain (PubChem)
tasimelteon
Sign in to saveAlso known as BMS-214778, Hetlioz®, VEC-162, VEC 162, BMS 214778, tasimeltéon, N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide
Tasimelteon, sold under the brand name Hetlioz, is a medication approved by the U.S. Food and Drug Administration (FDA) in January 2014, for the treatment of non-24-hour sleep–wake disorder (also called non-24, N24 and N24HSWD). In June 2014, the European Medicines Agency (EMA) accepted an EU filing application for tasimelteon and in July 2015, the drug was approved in the European Union for the treatment of non-24-hour sleep-wake rhythm disorder in totally blind adults, but not in the case of non-24 in sighted people.
Chemical data
- Formula
- C15H19NO2
- Molecular weight
- 245.32 g/mol
- IUPAC name
- N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide
- SMILES
- CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2
- InChIKey
- PTOIAAWZLUQTIO-GXFFZTMASA-N
- XLogP
- 2.2
- Polar surface area
- 38.3 Ų
- H-bond donors
- 1
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2014
- Admin. routes
- oral
- Indications
- liver disease, insomnia, kidney disease, major depressive disorder
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 245.141579
- Has use
- medication
Show 5 more facts
- chemical formula
- C₁₅H₁₉NO₂
- canonical SMILES
- CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2
- isomeric SMILES
- CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2
- World Health Organisation international non-proprietary name
- tasimelteon
- Commons category
- Tasimelteon
Sources (2)
via Wikidata · CC0
~4 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Development
- FDA approval
- Toxicity
- See also
- References
- External links
Tasimelteon, sold under the brand name Hetlioz, is a medication approved by the U.S. Food and Drug Administration (FDA) in January 2014, for the treatment of non-24-hour sleep–wake disorder (also called non-24, N24 and N24HSWD). In June 2014, the European Medicines Agency (EMA) accepted an EU filing application for tasimelteon and in July 2015, the drug was approved in the European Union for the treatment of non-24-hour sleep-wake rhythm disorder in totally blind adults, but not in the case of non-24 in sighted people.
The most common side effects include headache, somnolence, nausea (feeling sick) and dizziness.
Excerpted from Wikipedia’s “tasimelteon” article, available under the CC BY-SA 4.0 licence.